Related Experiment Video
Updated: May 10, 2026
Combination of High Ligation and Intraoperative Embolization Using Polidocanol for Treatment of Varicoceles
Published on: December 22, 2023
[Rapid regression of infantile haemangioma with 2% propranolol ointment]
A Mouhari-Toure1, K-D Azoumah, K Tchamdja
1Service de dermatologie, CHU, Kara, Togo. ambatoure@gmail.com
Insights
Topical 2% propranolol ointment rapidly reduced infantile haemangioma size by 75% in an infant. This treatment for infantile haemangioma showed significant regression with no observed adverse effects.
Area of Science:
- Dermatology
- Pediatrics
- Pharmacology
Background:
- Infantile haemangiomas are common benign vascular tumors in infants.
- Oral propranolol is a recognized effective treatment for severe infantile haemangiomas.
- Limited data exists on the efficacy and safety of topical propranolol for infantile haemangiomas.
Observation:
- A case study involving an 11-week-old female infant with two superficial infantile haemangiomas.
- Treatment administered was a topical 2% propranolol ointment.
- Lesion size reduction was monitored over 45 days.
Findings:
- Rapid and significant regression of infantile haemangiomas observed.
- Estimated 75% reduction in lesion size within 45 days of topical treatment.
- No adverse effects were reported during the treatment period.
Implications:
- Topical propranolol demonstrates potential as an effective and safe alternative for treating superficial infantile haemangiomas.
- Further clinical trials are warranted to establish optimal dosage, formulation, and treatment duration.
- This approach may offer a localized treatment option with potentially fewer systemic side effects than oral propranolol.
Background:
Oral propranolol produces dramatic results in severe infantile haemangioma. We report a case of rapid and significant regression of an infantile haemangioma in infant treated topically with 2% propranolol ointment.
Patients And Methods:
A female infant aged 11 weeks was seen as an outpatient for two infantile haemangiomas on the front of the left knee and the vulva. After parental consent was given, the child was treated with a topical preparation of 2% propranolol ointment prepared by the pharmacy. Regression was rapid and on the 45th day, lesion size had been reduced by an estimated 75%. No adverse effects were observed.
Discussion:
Topical propranolol appears to be effective and safe for the treatment of superficial haemangiomas. Clinical trials are required to determine the optimal dosage and pharmaceutical form, method of use and treatment duration.
